Selcaxen is identified for this website as a product containing 40 mg of selpercatinib. The specific manufacturer, marketing authorization holder and regulatory status of Selcaxen require product-specific verification.
Selpercatinib is a selective kinase inhibitor directed primarily at RET signaling. It is used in selected cancers in which RET gene fusions or RET mutations are identified and clinically relevant to treatment selection. Current U.S. labeling requires selection of patients according to the relevant RET alteration detected by an FDA-approved test.
Product identity
| Attribute | Information |
|---|---|
| Product | Selcaxen |
| Stated strength | 40 mg |
| Generic name | Selpercatinib |
| Drug class | RET kinase inhibitor |
| Therapeutic category | Targeted anticancer therapy |
| Route | Oral, subject to product documentation |
| Reference product | RETEVMO |
| Selcaxen manufacturer | Everest Pharmaceuticals Ltd. |
What is selpercatinib?
Selpercatinib is a kinase inhibitor designed to inhibit RET signaling. RET is a receptor tyrosine kinase involved in cellular signaling. Certain gene fusions or mutations can produce abnormal RET signaling that contributes to malignant growth.
What does 40 mg mean?
The 40 mg designation describes the stated amount of selpercatinib in the Selcaxen product unit. It should not be interpreted as a recommended daily dose.
Current U.S. RETEVMO labeling uses weight- and age-based regimens and includes 40 mg as one of the available capsule and tablet strengths.
Selcaxen and RETEVMO
RETEVMO is the established reference brand containing selpercatinib. It was initially approved in the United States in 2020.
Selcaxen should not be described as RETEVMO or as an identical product unless product-specific regulatory documentation establishes that relationship.
Why genetic testing matters
Selpercatinib treatment is based on identifying the relevant RET alteration. The specific alteration matters because RET fusions and RET mutations occur in different cancers and are associated with different treatment contexts.
Professional supervision
Because selpercatinib can cause liver injury, ILD/pneumonitis, hypertension, QT prolongation, bleeding and other adverse effects, treatment requires clinical monitoring.